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ess: b.izci@ed.ac.uk (BSummary Snoring and obstructive sleep apnoea/hypopnoea syndrome (OSAHS) are
often treated with mandibular repositioning splints (MRS), but the efficacy and
satisfaction of them has not been comprehensively addressed. A survey on the use of
and satisfaction with MRS was posted to 177 patients referred by a hospital
orthodontic department for custom-fitting of a MRS. Data were analysed using non-
parametric techniques. The response rate was 81% (n ¼ 144). Responders (30F,
114M) had mean (SD) age of 51 (11) years, apnoea+hypopnoea index (AHI) of 24 (21)
per hr and Epworth Score of 10 (5) at diagnosis, and had been supplied with their MRS
a median 7 (IQR 5–11) months previously. Fifty of the 144 patients (35%) had been
offered continuous positive airway pressure (CPAP) treatment but had declined or
abandoned this. Self-reported MRS use was 5 (2) h/night, with 74 of the 144 patients
(51%) continuing to use MRS at least occasionally at a median 7 months after fitting.
Survival analysis showed 12% still using MRS at 12 months. Epworth score fell slightly
with MRS therapy [2.4 (3.5); P ¼ 0:005] and 7 daytime and 2 nocturnal symptoms
improved in MRS users (all Po0:05). Marital satisfaction did not change with MRS.
Problems preventing MRS use in 70 non-users included: non-retention (n ¼ 12), sore
mouth (n ¼ 13) or jaw (n ¼ 7), difficulties falling asleep (n ¼ 10) or breathing
(n ¼ 7), excessive salivation (n ¼ 4), dental damage (n ¼ 4) and other problems
(n ¼ 3). Continued use of MRS therapy was associated with a higher number of teeth,
low marital satisfaction perceived by partners and greater improvement in
symptoms reported by patients and partners. Continuance with MRS may be low
and linked to tolerance problems.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserved.
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Obstructive sleep apnoea/hypopnoea syndrome
(OSAHS) is a condition characterised by repeated
episodes of upper airway closure during sleep,
resulting in nocturnal hypoxaemia and sleep frag-
mentation.1 Untreated OSAHS is associated with an
increased incidence of daytime sleepiness, motor
vehicle accidents, impaired social relationships and
quality of life.1–6 The treatment of OSAHS is
primarily focused on alleviating these symptoms.4–6
Continuous positive airway pressure (CPAP) is the
most common and highly effective treatment for
snoring and OSAHS. However compliance with nasal
CPAP is variable due to its inconvenient nature.7,8
Thus oral appliances (OAs) are considered as a
promising alternative, due to some advantages over
CPAP such as being less obtrusive, non-invasive,
silent and easy to use.5,9
Most OAs, including mandibular repositioning
splints (MRSs), are designed to hold the mandible
and/or tongue in a protruded posture during sleep,
thereby preventing upper airway occlusion.4,5,9
Studies using different techniques—such as cepha-
lometry,10–13 magnetic resonance imaging (MRI),14
video-endoscopy 15 and computed tomography 16
have demonstrated that OAs advance the mandible
and alter the volume of the upper airway.
Snoring is one of the most common and disturbing
symptoms for partners of patients due to the fact
that it decreases their sleep quality and may affect
their relationship. Thus, the insights of partners
can be valuable in determining whether patients
continue to use of the device and overcome its side
effects. Side -effects associated with the use of OAs
have been reported such as discomfort in the
temporo-mandibular joint (TMJ) or dental pain,
bite change, excessive salivation or dryness of the
mouth and there is the potential for adverse effects
on breathing.5,6,11,13,17–28 But recent developments
with OAs, specifically the adjustability of mandib-
ular advancement and the ability to titrate, may
significantly increase their efficacy for optimal
treatment 9,26,29 and increase the quality of life
for both patients with non-apnoeic snoring, mild to
moderate OSAHS or severe OSAHS patients who
could not tolerate CPAP and their partners.
It is important to define OAs’ long-term efficacy,
compliance and side effects. Early studies of OAs
either relied on a short time usage with a small
sample size, provided a small amount of data with
long-term usage or obtaining data in the awake
state and were based on effectiveness of symptoms
on side effects and maintenance requirements.4–6
Furthermore, no study exists which uses bed
partners’ sleep in determining the effectivenessof the device. Nor is there any research which
employs marital satisfaction to this end. Therefore,
more long-term studies are needed to define the
therapeutic role of OAs in different sleep disorders
related to upper airway obstruction. Thus, this
questionnaire-based retrospective study aims to
evaluate patient compliance, perceived efficacy,
satisfaction and side effects of MRS devices in the
treatment of patients who suffer from non-apnoeic
snoring to severe OSAHS.Subjects and methods
A survey was posted to 177 consecutive patients
referred from the Department of Sleep Medicine to
the Post-Graduate Dental Institute, Edinburgh
University for custom-fitting of intra-oral MRS
devices. A second survey was mailed to non-
responders two months later. Telephone contact
was subsequently attempted if no written response
was received from the second mailing. Written or
telephone response was achieved in 144 from 177
patients.
All subjects had a diagnostic sleep study to
determine their level of sleep-disordered breathing
before referral to the Dental Institute for MRS
treatment. No one with central sleep apnoea was
included in the study. OSAHS was defined as
apnoea+hypopnoea index (AHI) X5 with excessive
daytime sleepiness (Epworth sleepiness scale (ESS)
410). Patients were only accepted for MRS treat-
ment if periodontal status was considered ade-
quate. Excluded were those with pre-existing TMJ
problems, periodontal disease, maxillo-facial ab-
normalities and insufficient teeth in each arch to
enable the device to engage. Those offered MRS
treatment included a wide spectrum of patients
with 12 non-apnoeic [AHI=3 (1) per hr] and 58
apnoeic snorers without sleepiness [Mean AHI=
23(15)], 25 mild [AHI=9 (3)], 26 moderate [AHI=21
(4)], and 23 severe OSAHS [AHI=55 (28)]. Fifty
patients in the mild, moderate and severe OSAHS
patients’ groups [AHI=35 (27)] had not tolerated or
had failed to comply with CPAP. Although the
number of teeth present and the occlusal relation-
ships of the patients varied, all patients had at
least four of their own teeth remaining in each
arch, when the MRS was fitted.
Mandibular repositioning splint
MRS devices were individually manufactured and
fitted by the same orthodontist (JMcD) to pro-
duce approximately 80% of maximal comfortable
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clearance.The device was not titratable. The
device was manufactured from 1-MEDL dual lami-
nate material, moulded to fit the interior contours
of the hard palate and frontal dentition during
mandibular protrusion. This single position device
affixed to dentition from the interior with metal
Adams clasps, holding the mandible in a protruded
but closed-mouth manner. It did not provide full
occlusal coverage (Fig. 1).
Standard education about the device use, main-
tenance and possible side-effects were supplied.
All patients were followed up until the device was
as effective as workable. Re-moulding or adjust-
ment of the MRS was offered in all instances of
persisting or uncomfortable side-effects or lack of
symptomatic benefit. Patients had been fitted with
their MRS 1–31 months before receiving the survey.
Survey
The survey was based on a previous questionnaire
used inquiring about use of CPAP, sleepiness,
changes in function and symptoms with CPAP
therapy and CPAP-related problems.7 The survey
used in present study requested subjects and their
partners to record perceived changes in daytime
and nocturnal symptoms, sleepiness, marital har-
mony, MRS usage and side-effects from the MRS.
Symptoms and functions
Patients were asked to rate alterations in day-
time and nocturnal symptoms and functions on
a five-point scale corresponding to ‘much worse
(1)’, ‘worse (2), ‘no change (3)’, ‘better (4)’,
‘much better (5)’. Symptoms and functions were
snoring, breathing pauses, daytime sleepiness,Figure 1 Mandibular repositoning splints.concentration, memory, night time sleep quality,
work efficiency, tiredness, general health, mood,
ability to drive long distance safely. Partners also
rated patients’ snoring, breathing pauses and day-
time sleepiness separately as well as their (partner)
sleep quality.
Epworth sleepiness scale
The ESS provides a subjective estimate of patients’
daytime sleepiness in eight every-day situations
(each question scores 0–3, total=0–24). It has been
shown to have good test-retest reliability (r ¼ 0:82)
and internal consistency (Cronbach alpha=0.88).30
Higher ESS scores indicate greater daytime sleepi-
ness. The pre-treatment ESS scores were obtained
from a review of Department of Sleep Medicine’s
clinical records when the ESS was completed by
patients and partners at the diagnostic stage. The
follow-up ESS was contained in the survey. The
administration of follow-up ESS permitted both the
patient and their partners to rate their response
during their usage of MRS.
Side effects
The patients were given a list of side effects
comprising difficulty falling asleep, soreness of
mouth, soreness of jaw, excessive salivation,
difficulty in breathing, retention problems and
tooth damage. Additionally, the list of side effects
also included an item for ‘other problems’ to allow
for an open-ended report of problems not on the
list. If they had any of these problems then they
were requested to rate them on a five-point scale:
not a problem (0), minor problem (1), but able to
continue using MRS (2), unable to continue using
MRS (3).
ENRICH marital satisfaction questionnaire
(EMS) and marital-related behaviours
The ENRICH marital satisfaction (EMS) question-
naire is a 15-item Likert scale that includes 10
items assessing marital quality, whose score is
scaled according to an embedded 5 item idealistic
distortion score.31 It has an alpha coefficient of
0.81 and a 4-week test–retest reliability of 0.86.31
Its construct validity has been satisfactory in
previous research.31 The EMS was presented in a
format that allowed the patient and their partners
to retrospectively rate their response for the period
before starting MRS and during their usage of MRS.
In addition to the EMS, patients and partners
were asked to rate the frequency of three other
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ing, the number of cuddles/hugs shared, and the
number of disagreements or arguments.3 The
median EMS score of 46 in this study was chosen
as a cutoff to differentiate between less and more
martially satisfied patients.Self-reported MRS use
Patients were asked how many nights per week and
how many hours per night MRS was applied. The
survey was enhanced with diagnostic data obtained
from a review of Department of Sleep Medicine’s
clinical records of age, gender and AHI, and with
standard sleep questionnaires completed by pa-
tient and spouse, which included the ESS.Statistical analysis
Statistical analysis was performed using SPSS for
Windows, version 10 (SPSS inc., Chicago, IL, USA).
When the variables measured were either catego-
rical or not normally distributed, non-parametric
statistics (Mann–Whitney, Wilcoxon, Spearman rank
correlation and w2 tests) were used. T-test was
applied if variables were normally distributed. A P-
value less than 0.05 interpreted as statistically
significant. Descriptive data in tables are expressed
as means and SDS to clarify the direction of changes
in scores with treatment, as some median values
were zero. Survival analyses (Kaplan–Meier) were
used 32 to examine MRS use over the follow-up
period, and Mantel–Haenszel tests 33 to analyse
variables influencing continued MRS use. Contin-
uous variables were categorized by commonly used
clinical cutoffs or by median values.Table 1 Subjects’ characteristics and initial data.
Variable All Patients Us
N 177 74
Contacted 144 (81%) 74
Female/male 30/114 16
Mean (7SD) Age (yr) 51 7 11 51
Employed full time 102 (76%) 55
Marital situation 113 (81%) 59
Mean (7SD) AHI, events/h 24 7 21 22
Mean (7SD) ESS 10 7 5 10
History of snoring 140 (99%) 72
Snoring in all position 104 (78%) 49
Snoring in back and side 23 (17%) 12
History of unrefreshing sleep 66 (47%) 33
SD-Standard deviation, AHI-Apnoea hypopnoea index, ESS-EpworthResults
Response rate and self-reported MRS usage
One-hundred and forty-four from 177 patients
(81%) responded to the survey. Of the 144, 50
(35%) had been offered CPAP treatment but had
declined or abandoned this (Table 1). Of 144
patients in whom contact was made, 76 answered
the written survey and 68 by telephone. When
compared with patients who returned the ques-
tionnaires, those answering by telephone were
younger (49 (SD 11) versus 54 (10) years; Po0:01).
No other clinical or demographic variable was
different between the contact groups.
Responders (30 female, 114 male) averaged 51
(11) years with a mean AHI of 24 (21) events/h
during sleep study and ESS score of 10 (5) at
diagnosis (Table 1). At follow-up, responders had
been supplied with an MRS device a median 7 (IQR
5–11) months previously.Self-reported compliance
Self-reported MRS use was 5 (2) h/night, with 74 of
the 144 patients (51%) continuing to use MRS at
least occasionally at a median 7 months after
fitting. A Kaplan–Meier plot of the percentage
of patients including both users and non-users
showed that 12% were still using MRS at the end
of 12 months. (Fig. 2). Thirty-seven of these 74
current users (50%) reported wearing their MRS
device every night. Within the 144 patients,
70 (49%) patients reported they were not now
using their MRS devices at all (Table 1). Ninety
six percent of the 70 patients abandoning MRS
therapy reported no benefit, or indeed reported aers Non-users CPAP failure/ refuser
70 50
(100%) 70 (100%) 50 (100%)
/58 14/56 11/39
7 10 51 7 10 54711
(76%) 47 (75%) 37 (80%)
(80%) 54 (81%) 39 (81%)
7 16 25 7 26 35727
7 5 10 7 6 1276
(99%) 68 (99%) 50 (100%)
(74%) 55 (82%) 37 (84%)
(18%) 11 (16%) 6 (14%)
(46%) 33 (48%) 23 (48%)
sleepiness scale.
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cant differences in age, AHI, ESS scores at diagnosis
and frequency of snoring between MRS users and
non-users (all P40:05Þ: The mean AHI and ESS
scores (baseline data) and subjects’ characteristics
for users and non-users are given in Table 1.
Sleepiness with MRS
ESS scores for patients, rated both by patients and
partners, improved marginally but significantly
after MRS therapy in users (Table 2). Changes in
ESS score showed significantly better improvements
in users than in non-users of MRS (Po0:05) (Table 2).
Changes in symptoms and function during
MRS treatment period
Snoring, breathing pauses, daytime sleepiness,
concentration, night time sleep quality, workFigure 2 Percentage of patients using MRS versus time.
Table 2 Changes in Sleepiness with MRS (Mean 7 SD).
Pre-MRS
Users (n ¼ 74)
ESS (patient) 1076
ESS (partner) 1075
Non-users (n ¼ 70)
ESS (patient) 976
ESS (partner) 976
Users
Diff in ESS (patient) 2.473.5
Diff in ESS (partner) 2.374.5
SD-Standard deviation, ESS-Epworth sleepiness score, Diff in-diffeefficiency, tiredness, general health and mood as
rated by patients showed significantly greater
improvements in users than in non-users of MRS
(Table 3). Also snoring, breathing pause and day-
time sleepiness as rated for patients by partners
improved in continuing users of MRS more than in
non-users (Table 3). The same was true of partners’
sleep quality (Table 3). There were no significant
improvements in memory or ability to drive long
distance safely with MRS use.
Changes in marital satisfaction with MRS
treatment
Amongst users, patients and their partners re-
ported an increase in sharing the same room after
MRS usage. However, patients and their partners
did not report any other improvements in marital
satisfaction with MRS (Table 4). MRS usage corre-
lated weakly with changes in sharing the same
room and cuddling in all patients (users and non-
users), and also with partners’ reports of changes
in sharing the same bedroom (r ¼ 0:320:5; Po0:01
– Po0:05).
Side effects with MRS treatment
Reported side effects of MRS treatment were more
common for non-users than for current users (all
Po0:001), although both current users and non-
users reported frequent side effects. There were no
serious complications reported. Problems were
rated as at least sometimes preventing MRS use in
non-users and users. Problems preventing MRS use
in 70 non-users included: non-retention (n ¼ 12),
sore mouth (n ¼ 13) or jaw (n ¼ 7), difficulties
falling asleep (n ¼ 10) or breathing (n ¼ 7), ex-
cessive salivation (n ¼ 4), dental damage (n ¼ 4)
and other problems such as difficulty swallowingPost-MRS P
775 o0.001
875 0.001
876 40.3
977 40.3
Non-users
174 0.005
0.0570.2 0.002
rences in.
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Table 3 Changes in Symptoms during MRS treatment (Mean 7 SD).
Measures Users n ¼ 74 % RI Non-users n ¼ 70 % RI P
Patient rating
Snoring 4.370.7 86 3.370.9 23 o0.001
Breathing pause 4.070.9 62 3.270.6 16 o0.001
EDS 4.070.9 50 3.170.7 9 o0.001
Mood 4.070.8 47 3.170.5 9 o0.001
Concentration 3.370.7 29 3.070.2 2 0.04
Night-time sleep quality 4.070.8 71 3.070.4 7 o0.001
Work efficiency 3.570.7 39 3.270.2 5 0.001
Tiredness 3.770.9 59 3.070.4 5 o0.001
General health 3.670.9 44 3.070.4 2 o0.001
Memory 3.170.7 20 3.070.3 0 40.06
Ability to drive long distances 3.470.8 25 3.170.2 5 40.07
Partner rating
Snoring 4.370.7 86 3.670.8 47 0.003
Breathing pause 4.070.9 59 3.570.8 26 o0.04
EDS 3.870.8 51 3.270.4 16 0.008
Partner sleep quality 4.170.7 80 3.770.8 47 0.04
SD-Standard deviation, RI-Reporting improvement, EDS-Excessive daytime sleepiness
Table 4 Changes in marital satisfaction with MRS treatment (Mean 7 SD).
Patient rating Users n ¼ 74 Non-users n ¼ 70
% RI P % RI P
Sleeping in the same room 172 30 o0.03 0.170.4 5 40.3
Having a cuddle 172 19 40.1 0.271 0 40.3
Enrich marital satisfaction 0.274 21 40.9 0.170.01 0 41
Partner rating Users Non-users
Sleeping in the same room 172 30 0.02 0.170.5 6 40.3
Having a cuddle 0.472 24 40.1 –0.471.3 0 40.3
Enrich marital satisfaction 277 11 40.3 0.170.01 0 41
SD: Standard deviation, RI: Reporting improvement.
B. Izci et al.342and dry mouth (n ¼ 3). Ten patients noted pro-
blems but did not specify these. The problems for
users were non-retention (n ¼ 1), sore mouth
(n ¼ 1) or jaw (n ¼ 1), difficulties falling asleep
(n ¼ 10), excessive salivation (n ¼ 2) and other
problems (n ¼ 1). None of the continuing MRS users
had problems with dental damage or difficulties in
breathing.Factors influencing MRS usage
We sought associated factors related to compliance
with MRS therapy from baseline data and from
variables obtained after beginning MRS therapy(X1 mo). The factors were patient-related (age,
sex, occupation, marital situation and satisfaction,
and number of teeth), disease-related (symptoms
at diagnosis; snoring, refreshment after sleep,
daytime somnolence, driving problems, baseline
ESS score, AHI), and treatment-related (MRS/CPAP
treatment, changes in symptoms with MRS and side
effects with MRS) variables.
Neither age, gender, occupation, marital situa-
tion, diagnostic AHI, baseline symptoms, nor
diagnostic ESS were associated with continuing
MRS usage (P40:09). This analysis indicated that
continued use of MRS therapy was associated with a
greater number of teeth, with low marital satisfac-
tion ratings by partners before starting MRS, and
ARTICLE IN PRESS
Table 5 Mantel–Haenszel tests: variables influencing MRS use.
Factors OR (95% CI) P-value
1.Influencing continued MRS Use
Number of teetho12 versus X12 0.16 (0.05–0.53) 0.004
Less snoring 0.05 (0.02–0.13) 0.0001
Less breathing pauses 0.20 (0.04–0.32) 0.0001
Improved sleep quality 0.03 (0.008–0.12) 0.0001
Improved tiredness 0.04 (0.008–0.17) 0.0001
Partner’s reports
Less snoring 0.15 (0.04–0.55) 0.008
Less breathing pauses 0.24 (0.07–0.85) o0.05
Improvement in sleepiness 0.18 (0.04–0.72) o0.03
Improvement in partner sleep quality 0.23 (0.07–0.77) o0.04
Poor marital satisfaction before using MRS 5.63 (1.34–23.63) o0.04
2.Influencing stopping MRS use
Difficulty falling sleep/frequent awakening 15 (1.83–122.95) 0.005
Soreness of mouth, teeth/gums 19.1 (2.39–152.82) 0.001
Soreness of jaw/jaw joint 9.39 (1.11–79.61) 0.04
Difficulty in breathing 1.23 (1.05–1.37) 0.01
Non-retention 1.44 (1.17–1.78) 0.0001
95% CI: 95% confidence interval.Odds ratios (OR) comparing nonusers to users.
Clinical audit of subjects with snoring and OSAHS fitted with MRS 343with greater improvements in symptoms reported
by patients and partners. Stopping MRS use was
associated significantly with higher side effects
score. Table 5 shows odds ratios relating nonusers
to users for these variables where there was a
significant difference between the two groups.
The effects of CPAP failures/refusal on the
usage and success of MRS:
Usage of MRS was not significantly affected by
whether a patient was a CPAP failure or refuser
(P40:3). Of 50 CPAP failures/refusers, as 46% (23)
indicated that they were still using their MRS at
least occasionally, and in these usage averaged 3%
(3) h/night. Those CPAP failures/refusers who con-
tinued to use MRS benefited from it. ESS scores,
rated by these patients, improved significantly
after MRS therapy, with pre- and post-MRS ESS
scores of 10 (6) and 9 (6), respectively (Po0:02).
However, ESS scores, rated by their partners, did
not change with MRS therapy.Discussion
This is a retrospective and self-reported follow-up
study, on an individual mandibular repositioning
device. Despite these limitations, the results
suggest that MRS helped patients’ daytime and
nocturnal symptoms and partners’ sleep quality asevidenced by symptomatic improvement from
patient and partner reports and greater improve-
ments in MRS users than non-users. However,
continuing use of the MRS by patients a median of
7 (IQR 5–11) months after fitting was low. Half the
patients had abandoned the MRS completely and
only one quarter of the total sample used the MRS
nightly.
The present results, though using a different MRS
device, closely agree with this of a similar study in
a slightly smaller patient group.28 However, we
have extended their outcome measures by examin-
ing marital satisfaction and a more extensive range
of side-effects and asked which of these prevented
MRS usage.
Compliance rate with OA treatment differs,
depending on the appliances’ design, the particular
study and the duration of treatment. Our compli-
ance rate, 51% of patients wearing MRS average 5
h/night at a median 7 months after fitting, is
consistent with previous studies.5,23,28 However,
survival analysis showed that this percentage
decreased to 12% at the end 12 months. McGown
et al. for instance, reported that 55% of their
patients claimed to have used their splint on
average 6.6 h/night regularly over 1 year.28 In
another study, patients’ compliance at the end of
one year was 60%, but dropped to 48% at the end of
second year.23 In contrast, however, Marklund et al.
reported a higher compliance rate (76%) in a long
term study.34 In addition, Pancer et al. reported
that compliance was 86% followed for almost 1
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ance with OAs can not be proved objectively. As
reported by Engleman et al. subjective CPAP
compliance (5.8SD2 h/night) is higher than objec-
tive compliance (5.1SD2.5 h/night).7 The compli-
ance can also change over time. In a large follow-up
CPAP study, compliance rate decreased from 84% to
68% in 4 years (a median usage of 5.7 h per night).8
The effectiveness and patient satisfaction of OA
was compared to CPAP 6,17–21 in a recent systematic
review6 and several randomised controlled
trials.6,17–21 These studies showed that OAs had
greater satisfaction and lesser side effects com-
pared to CPAP.17–21 Although both OA and CPAP
were effective in the studies, OAs did not decrease
AHI,17–21 daytime17–19 or nocturnal symptoms17,18,21
as much as CPAP. However, patients’ preference
were for OAs in four studies17,18,20,21 and was for
CPAP in one study.19
It is not known exactly why such a large number
of patients abandoned MRS in present study. Our
results showed that the main reasons for stopping
MRS usage are related to lack of benefit and side
effects from MRS cited by patients, but these were
by nature subjective and not confirmed by objec-
tive tests. In the current study, problems prevent-
ing MRS use in 70 non-users included: non-retention
(n ¼ 12), sore mouth (n ¼ 13) or jaw (n ¼ 7),
difficulties falling asleep (n ¼ 10) or breathing
(n ¼ 7), excessive salivation (n ¼ 4), dental da-
mage (n ¼ 4) and other problems (n ¼ 3). Primary
side effects stopping MRS usage were difficulty with
retention, sore mouth and jaw, falling asleep and
breathing. The results from previous studies re-
lated to side effects conflict with one another.
Schmidt–Nowara et al. in the meta-analysis re-
ported that TMJ pain and occlusal changes are rare
and that oral discomfort is a common side effect
but subside with regular use and adjustment of fit.5
In a study using a mandibular advancement splint,
it was reported that side effects were dryness of
mouth (21%), excessive salivation (19%), bruxism
(9%), and gum irritation (7%). However, mild jaw
discomfort on waking was present during initiation
of treatment in 37 (65%) of the 57 as patients.27
Pantin et al. showed on minor or temporary dental
side effects in patients who had worn OAs for a
mean of 31 (SD18) as months. Nevertheless, they
detected occlusal changes in 14% of their pa-
tients.25 Pancer et al. reported that the most
common side effects with an appliance, the
Thornton anterior positioner, were teeth or jaw
discomfort occurring in 83% and 81% of 121
patients, respectively.24 In a recent evaluation of
22 patients treated with a removable mandibular
advancement appliance, Fritsch et al. also found asignificant decrease in intermolar position and a
decrease in overjet and overbite after 12–30 as
months.22 In this study, even though side effects,
such as mucosal dryness, hypersalivation, transient
tooth, or jaw pain were common, occurring in
32–86% of patients, they were not so severe that
patients discontinued treatment.22 Thus, side
effects were less frequent but reported MRS
discontinuation more common in our study than in
others.
In the analysis of continued MRS use, the
outcome indicated that a relief of clinical symp-
toms are major factors to support MRS use.
Specially, improvement in snoring, breathing
pauses and sleep quality noticed by patients and
partners, and partner’s sleep quality were asso-
ciated with continuing MRS usage. Our results
confirmed the previous study which tried to
establish the factors influencing OA usage with
variable results.28 Additionally, our findings demon-
strated that the number of teeth (X12) when OA
was fitted and poor marital satisfaction before
commencing MRS were factors associated with
continuing MRS usage. Thus number of teeth may
well be an important clinical consideration in this
type of MRS. It has been previously suggested that 8
teeth should be in each jaw to aid sufficient
retention for a permanent mandibular protrusion
with an OA.9 In our study, the number of teeth can
be an important factor stopping MRS usage.
The device’s design, anatomical skeletal factors
influencing the degree of vertical and sagittal
opening, possible displacement of the mandible,
the enlargement of the pharyngeal airway-space,
and sleep position might play important role in
treatment efficacy with OA.5,9,11,15,16 In the rando-
mised controlled trial the best outcome for OA
achieved with an adjustable appliance.26 MRSs used
in this audit were not titratable and adjustable
expressly by design. However, the MRS designed by
the same dentist (JMcD) accomplished a decrease
in subjective daytime and nocturnal symptoms in
current study and a previous study and many
patients also obtain good results for objective
efficacy in this previous study.19 Bloch et al.
compared two different custom-fitted MRS devices
in a randomised control trial. The simpler model
resembling those used in the current study
achieved better efficacy.35 In another study, Mayer
et al. were able to treat patients with mild to
severe OSAHS effectively using Esmarch devices
similar to ours.10 Furthermore, Marklund et al.34
used an individually designed, one-piece device
throughout the entire 10.5-year period, even when
they changed the material from hard acrylic to soft
elastomer in the middle of the study. The results
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between these two appliances.
This low rate of MRS usage may be explained by
differences in patient selection or survey methods.
For example, while OAs have been commonly
recommended for mild OSAHS,4,5,9 our study
included a wide spectrum of patients with non-
apneic snoring to severe OSAHS (AHI range from
1–164). However, in our study severity of disease
was not related to MRS usage and some studies also
showed that patients with severe OSAHS benefited
reasonably from OAs treatment.5,10,11,24,26,36 In the
current study, there were only 23 patients with
clinically significant sleepiness (ESS410) and an
AHI430/h. Eighteen of 23 patients had failed or
refused to use CPAP. In addition, our survey was
carried out by the sleep centre and not by the
orthodontic service, and thus the patients were not
in a dependent role with their questioner as far as
their MRS was concerned.
There was no evidence from our study that MRS
resulted in improved marital satisfaction. This is
consistent with results from a randomised crossover
trial with CPAP versus placebo, which showed that
CPAP did not improve marital as satisfaction.3 In
another recent controlled study, which examined
the relationship between untreated men with
OSAHS and their partners’ marital satisfaction,37
they found OSAHS was not associated with reduced
marital satisfaction although co-sleeping was im-
paired. If OSAHS or snoring were not the primary
cause of marital disharmony, then either MRS or
CPAP usage would not be expected to have a major
effect on marital satisfaction. In other words,
snoring or apnoeas could be secondary explanations
for a pre-existing primary problem. O’Sullivan and
co-workers made first reporting that OA use
resulted in couples being able to sleep in the same
room.27 Our results concurred with theirs; namely
that patients and their partners reported that
sharing the same room improved after MRS usage.
This may be connected with our other finding that
improvement in patients’ snoring could be a
positive reinforcement from their partners. How-
ever, when partners do not see benefits this may
discourage patients from using their device.28 In
the current study, only the frequency of cuddling
and of sharing the same room correlated with MRS
usage. Also, as mentioned above, low marital
satisfaction perceived by partners before using
MRS was associated with continuing MRS use. Thus
a partner annoyed by snoring may encourage their
partner to use OA.
Limitations of our own study include its retro-
spective, questionnaire-based character, the lack
of objective assessment of the effect of MRS andthe type of MRS used. Questionnaires have limita-
tions but these were minimised by ensuring a high
(81%) response rate. It would have been preferable
to measure compliance objectively, but techniques
for this remain in a developmental stage. The other
limitation is that this is based on a single MRS
device, as mentioned above. Additionally, the
device did not cover all the teeth, a fact which
could have contributed to the problems with
retention,although patients not benefiting from
the MRS were offered revision or provision of a
new device at no cost. Nevertheless these results
cannot be generalised to all devices, but they raise
the challenge to users of other devices to prove
greater efficacy and better use.
In conclusion, MRS may offer a simple and
effective alternative treatment of non-apnoeic
snoring to severe OSAHS in selected patients who
are unwilling or unable to use nasal CPAP. However,
patients’ use of MRS devices and their therapeutic
response to this treatment was disappointing.References
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